Pharmamarketeer

AstraZeneca requests emergency authorisation for COVID-19 drug

AstraZeneca requests emergency authorisation for COVID-19 drug

AstraZeneca has submitted an FDA request for Emergency Use Authorisation (EUA) for AZD7442, a long-acting antibody combination (LAAB) for the treatment of symptomatic COVID-19.

If the approval is granted, AZD7442 would be the first LAAB to receive an EUA for COVID-19 prevention. It has demonstrated a statistically significant reduction in the risk of developing symptomatic COVID-19 compared to placebo, and is the first LAAB with Phase III data to do so.

AstraZeneca requests emergency authorisation for COVID-19 drug | Pharmafile

Advertentie(s)